Likelihood of Post-COVID Condition in people with hybrid immunity; data from the German National Cohort (NAKO).

Autor: Mikolajczyk R; Institute for Medical Epidemiology, Biometrics, and Informatics, Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle (Saale), Germany. Electronic address: rafael.mikolajczyk@uk-halle.de., Diexer S; Institute for Medical Epidemiology, Biometrics, and Informatics, Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle (Saale), Germany., Klee B; Institute for Medical Epidemiology, Biometrics, and Informatics, Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle (Saale), Germany., Pfrommer L; Institute for Medical Epidemiology, Biometrics, and Informatics, Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle (Saale), Germany., Purschke O; Institute for Medical Epidemiology, Biometrics, and Informatics, Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle (Saale), Germany., Fricke J; Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany., Ahnert P; Institute for Medical Informatics, Statistics and Epidemiology, Universität Leipzig, Leipzig, Germany., Gabrysch S; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Public Health, Berlin, Germany; Research Department 2, Potsdam Institute for Climate Impact Research (PIK), Member of the Leibniz Association, Potsdam, Germany; Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany., Gottschick C; Institute for Medical Epidemiology, Biometrics, and Informatics, Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle (Saale), Germany., Bohn B; NAKO e.V., Heidelberg, Germany., Brenner H; Division of Clinical Epidemiology and Aging Research, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Buck C; Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany., Castell S; Department for Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany., Gastell S; NAKO Study Centre, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany., Greiser KH; Division of Cancer Epidemiology, DKFZ Heidelberg, Heidelberg, Germany., Harth V; Institute for Occupational and Maritime Medicine Hamburg (ZfAM), University Medical Centre Hamburg-Eppendorf (UKE), Hamburg, Germany., Heise JK; Department for Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany., Holleczek B; Krebsregister Saarland, Saarbrücken, Germany., Kaaks R; Division of Cancer Epidemiology, DKFZ Heidelberg, Heidelberg, Germany., Keil T; Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany; Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany; State Institute of Health I, Bavarian Health and Food Safety Authority, Erlangen, Germany., Krist L; Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany., Leitzmann M; Institute of Epidemiology and Preventive Medicine, Regensburg, Germany., Lieb W; Institute of Epidemiology, Kiel University, Kiel, Germany., Meinke-Franze C; Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany., Michels KB; Institute for Prevention and Cancer Epidemiology, Faculty of Medicine and Medical Centre, University of Freiburg, Freiburg, Germany., Velásquez IM; Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association (MDC), Molecular Epidemiology Research Group, Berlin, Germany., Obi N; Institute for Occupational and Maritime Medicine Hamburg (ZfAM), University Medical Centre Hamburg-Eppendorf (UKE), Hamburg, Germany., Panreck L; NAKO e.V., Heidelberg, Germany., Peters A; Institute of Epidemiology, Helmholtz Zentrum München - German Research Centre for Environmental Health (GmbH), Neuherberg, Germany; Chair of Epidemiology, Institute for Medical Information Processing, Biometry and Epidemiology, Medical Faculty, Ludwig-Maximilians-Universität München, Munich, Germany., Pischon T; Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association (MDC), Molecular Epidemiology Research Group, Berlin, Germany., Schikowski T; IUF-Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany., Schmidt B; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany., Standl M; Institute of Epidemiology, Helmholtz Zentrum München - German Research Centre for Environmental Health (GmbH), Neuherberg, Germany; German Centre for Lung Research (DZL), Munich, Germany., Stang A; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany., Völzke H; Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany., Weber A; Institute of Epidemiology and Preventive Medicine, Regensburg, Germany., Zeeb H; Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany; Health Sciences Bremen, University of Bremen, Bremen, Germany., Karch A; Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.
Jazyk: angličtina
Zdroj: The Journal of infection [J Infect] 2024 Aug; Vol. 89 (2), pp. 106206. Date of Electronic Publication: 2024 Jun 17.
DOI: 10.1016/j.jinf.2024.106206
Abstrakt: Objectives: The risk of Post-COVID-19 condition (PCC) under hybrid immunity remains unclear.
Methods: Using data from the German National Cohort (NAKO Gesundheitsstudie), we investigated risk factors for self-reported post-infection symptoms (any PCC is defined as having at least one symptom, and high symptom burden PCC as having nine or more symptoms).
Results: Sixty percent of 109,707 participants reported at least one previous SARS-CoV-2 infection; 35% reported having had any symptoms 4-12 months after infection; among them 23% reported nine or more symptoms. Individuals, who did not develop PCC after their first infection, had a strongly reduced risk for PCC after their second infection (50%) and a temporary risk reduction, which waned over 9 months after the preceding infection. The risk of developing PCC strongly depended on the virus variant. Within variants, there was no effect of the number of preceding vaccinations, apart from a strong protection by the fourth vaccination compared to three vaccinations for the Omicron variant (odds ratio = 0.52; 95% confidence interval 0.45-0.61).
Conclusions: Previous infections without PCC and a fourth vaccination were associated with a lower risk of PCC after a new infection, indicating diminished risk under hybrid immunity. The two components of risk reduction after a preceding infection suggest different immunological mechanisms.
Competing Interests: Declaration of Competing Interest None.
(Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: